Bill > SB2370

This bill provides for a legislative management study during the 2025-26 interim regarding prescription drug transparency reporting under the federal drug discount program (known as 340B program). The study aims to establish reporting requirements for various healthcare entities participating in the program, including hospitals, contract pharmacies, federally qualified health centers, drug manufacturers, pharmacy benefits managers, and health insurers. The legislative management will explore specific data elements that should be reported, methods of reporting and sharing data to benefit North Dakota patients, confidentiality considerations, and potential enforcement mechanisms like civil penalties for non-reporting. The study will involve extensive stakeholder input from professional associations, healthcare providers, regulatory agencies, and industry representatives. Upon completion, the legislative management will report its findings and recommendations to the 70th legislative assembly, potentially including draft legislation to implement the study's conclusions. The goal is to develop public policy that directly benefits patients by increasing transparency in the 340B drug discount program.

Budget and Finance, Government Affairs

https://ndlegis.gov/assembly/69-2025/regular/bill-overview/bo2370.html